| |
original article |
Date |
Title |
Authors Max. 6 Authors |
| 1 |
[GO] |
2026―May―04 |
Point Substitution N33D in the Light Chain of Neutralizing Antibody REGN10987 Increases the Fab Affinity to RBD of Omicron BA.1 SARS-CoV-2 Variant. In Silico Study |
D. E. Nolde, M. V. Kocharovskaya, A. V. Popov, M. P. Kirpichnikov, E. N. Lyukmanova, Z. O. Shenkarev |
| 2 |
[GO] |
2025―Dec―15 |
Composition of Lipophilic Components of Caragana jubata (Pall.) Poir. and Inhibitory Activity Against the Main Protease of SARS-CoV-2 |
T. P. Kukina, I. A. Elshin, O. I. Salʼnikova, P. V. Kolosov, S. Khashchuluun, B. Badmaarag, S. Chimidtseren, O. Erdenezayaa, Ts. Sandag, D. A. Karakay, M. A. Pukhnacheva, A. A. Nefedov, V. Yu. Chirkova, S. V. Belenkaya, D. N. Shcherbakov |
| 3 |
[GO] |
2025―Apr―06 |
Investigation of Quinoxaline-1,2,3-triazole Derivatives for Targeting SARS-CoV-2 via RBD Binding and PLpro Inhibition |
Amr Negm, Ahmad R. Rabee, Hamida Abdel-Hamid, Samah A. Nasr, Doaa A. Ghareeb, Rabab S. Ibrahim, Mohammed B. Hawsawi, Ahmed M. Abdelmoneim, Magda M. F. Ismail, Mohammed Salah Ayoup |
| 4 |
[GO] |
2024―Dec―16 |
Novel Pyridazine-3(2H)-one Derivatives as SARS-CoV-2 Inhibitors: Design, Synthesis, Characterization, Molecular Docking, and Their In Silico ADMET Studies |
Kilol M. Rabara, Jaydeep N. Lalpara, Gaurang G. Dubal |
| 5 |
[GO] |
2024―Oct―09 |
Synthesis of SARS-CoV-2 Spike Glycoprotein Peptide Fragments and Study of Their Binding to Human Blood Cells |
О. V. Gribovskaya, V. V. Yanchenko, A. M. Tsygankov, V. P. Martinovich |
| 6 |
[GO] |
2024―Jun―05 |
Ultrasound Assisted Synthesis of Phenothiazine Based Chalcone Derivatives, Their Antibacterial Studies and Molecular Docking Against COVID-19 Virus Spike Protein Inhibitor |
K. Venkatesan, N. Hussain Basha, T. Jagadish, P. Vishnuvardhan Reddy, Hussain Shaik, M. Pasupathi |
| 7 |
[GO] |
2024―Jan―10 |
Virtual Screening of Orally Active Lead Compounds of Pearl Millet and Their Structural Activity Against Target Protein of COVID-19 |
Adarsh Kumar Shukla, Ashwani Kumar |
| 8 |
[GO] |
2023―Dec―25 |
Composition of Lipophilic Components of Rhododendron adamsii Rehd. Ether Extract and Activity against SARS-CoV-2 Main Protease |
T. P. Kukina, I. A. Elshin, O. I. Sal’nikova, P. V. Kolosov, Ts. Sandag, D. A. Karakai, M. A. Bondareva, A. A. Nefedov, V. Yu. Chirkova, E. A. Sharlaeva, S. V. Belen’kaya, D. N. Shcherbakov |
| 9 |
[GO] |
2023―Nov―23 |
Synthesis of 5-Halo-2ʹ-Azido Derivatives of Cytidine and N-Hydroxycytidine and Evaluation of Their Antiviral Activity on a Panel of RNA Viruses, Including SARS-CoV-2 |
P. N. Kamzeeva, E. S. Kolpakova, E. V. Karpova, M. O. Borodulina, E. V. Yakovchuk, V. A. Alferova, A. A. Chistov, E. S. Belyaev, L. I. Kozlovskaya, A. V. Aralov |
| 10 |
[GO] |
2023―Aug―21 |
Condensates of SARS-CoV-2 Nucleoprotein on Viral RNA and Their Small Molecule Modulators (A Review) |
Yu. I. Svetlova, Yu. I. Pavlova, A. V. Aralov, A. M. Varizhuk |
| 11 |
[GO] |
2023―Aug―17 |
Species-Level Identification of SARS-CoV-2 by an E Gene Conservative Site |
S. A. Lapa, A. A. Shingareva, E. B. Faizuloev, Yu. I. Ammour, V. E. Shershov, A. V. Chudinov |
| 12 |
[GO] |
2023―Aug―17 |
Synthesis of Liposomes Conjugated with CpG-Oligonucleotide and Loaded with a Set of T-Cell Epitopes of the SARS-CoV-2 Virus |
D. S. Tretiakova, T. L. Azhikina, I. A. Boldyrev, E. V. Svirshchevskaya, E. L. Vodovozova |
| 13 |
[GO] |
2023―May―11 |
Effective Drug Candidates against Global Pandemic of Novel Corona Virus (nCoV-2019): A Probability Check through Computational Approach for Public Health Emergency |
C. G. Bonde, J. Gawad, R. P. Bhole, S. C. Bonde, R. V. Chikhale |
| 14 |
[GO] |
2023―Mar―01 |
Proof-of-Concept Study of Liposomes with a Set of SARS-CoV-2 Viral Peptidic T-Cell Epitopes as a Vaccine |
D. S. Tretiakova, A. S. Alekseeva, N. R. Onishchenko, I. A. Boldyrev, N. S. Egorova, D. V. Vasina, V. A. Gushchin, A. S. Chernov, G. B. Telegin, V. A. Kazakov, K. S. Plokhikh, M. V. Konovalova, E. V. Svirshchevskaya, E. L. Vodovozova |
| 15 |
[GO] |
2022―Dec―23 |
Erratum to: Prospects for the Use of Marine Sulfated Fucose-Rich Polysaccharides in Treatment and Prevention of COVID-19 and Post-COVID-19 Syndrome |
M. V. Kiselevskiy, N. Yu. Anisimova, M. I. Bilan, A. I. Usov, N. E. Ustyuzhanina, A. A. Petkevich, I. Zh. Shubina, G. E. Morozevich, N. E. Nifantiev |
| 16 |
[GO] |
2022―Oct―20 |
Prospects for the Use of Marine Sulfated Fucose-Rich Polysaccharides in Treatment and Prevention of COVID-19 and Post-COVID-19 Syndrome |
M. V. Kiselevskiy, N. Yu. Anisimova, M. I. Bilan, A. I. Usov, N. E. Ustyuzhanina, A. A. Petkevich, I. Zh. Shubina, G. E. Morozevich, N. E. Nifantiev |
| 17 |
[GO] |
2021―Aug―21 |
Drugs that Might Be Possibly Used for Treatment of COVID-19 Patients |
Mehdi Salih Shihab, Baram Hamah-Ameen |
| 18 |
[GO] |
2021―Jun―11 |
A Mini Review on Discovery and Synthesis of Remdesivir as an Effective and Promising Drug against COVID-19 |
E. Zarenezhad, S. Behrouz, M. Farjam, M. N. Soltani Rad |
| 19 |
[GO] |
2021―Mar―20 |
Synthesis, Molecular Docking, In Silico ADME Predictions, and Toxicity Studies of N-Substituted-5-(4-Chloroquinolin-2-yl)-1,3,4-Thiadiazol-2-Amine Derivatives as COVID-19 Inhibitors |
Walaa S. El-Serwy, Weam S. El-Serwy |
|
